Investing where it matters most
We have always viewed R&D as essential to our growth. That is why we are committed to making a significant investment towards it year after year. In fact, over 11% of our employees are engaged full-time in R&D, and a total amount of €106 million was invested in R&D in 2020.
Decades of innovations
Thanks to our continuous investment in R&D and dedicated specialized teams, we have been at the forefront of decades of landmark discoveries, including the first direct-reading pH/blood gas analyzer and the invention of CO-oximetry, the first fully automated coagulation system, as well as more than 50 biomarkers in the autoimmunity market.